| Level I | Good quality evidence |
Systematic review of RCTs with consistent findings High quality individual RCT |
| Level II |
Limited quality patient orientated evidence |
Systematic review of lower quality studies or studies with inconsistent findings Low quality clinical trial Cohort studies Case-control studies |
| Level III | Other |
Consensus guidelines, extrapolations from bench research, usual practice, opinion, disease-oriented evidence (intermediate or physiologic outcomes only), or case series |
[19] Ciprofloxacin, oral (caution - concomitant use with ACE-inhibitor/ARB): Savage R. Ciprofloxacin, enalapril and acute kidney injury: Strengthening of a drug Interaction signal. WHO Pharmaceuticals Newsletter : 16-21, No. 1, 201. http://www.who.int/medicines/publications/WHO-Pharmaceuticals_Newsletter_No1-2018.pdf?ua=1
Ciprofloxacin, oral (caution - concomitant use with ACE-inhibitor/ARB): Bird ST, Etminan M, Brophy JM, Hartzema AG, Delaney JA. Risk of acute kidney injury associated with the use of fluoroquinolones. CMAJ. 2013 Jul 9;185(10):E475-82. https://www.ncbi.nlm.nih.gov/pubmed/23734036